Eli Lilly, Sitryx sign potential $880m deal to develop immunometabolic medicines

This article was originally published here

Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The new targets

The post Eli Lilly, Sitryx sign potential $880m deal to develop immunometabolic medicines appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply